$65.670
-1.799 (-2.74%)Zum Schluss
TVTX-News
TVTX-Events
Digital Turbine Shares Rise 24.3% After Earnings
Stock futures were mixed following this week's already sharp gains after another slate of big earnings reports. While SpaceX slipped after its first report as a public company, gains from Booking, Arista, and others weighed on futures. Crude oil futures were also lower amid optimism over a potential U.S.-Iran deal to reopen the Strait of Hormuz.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Digital Turbineup 24.3%Travere Therapeuticsup 12.4%Arista Networksup 9.2%Ultragenyxup 6.4%Bookingup 5.7%Wynn Resortsup 5.5%Paylocityup 3.4%ALSO HIGHER -Sight Sciencesup 9.6% after receiving FDA 510clearance of the Omni Ultra Surgical SystemDOWN AFTER EARNINGS -Teradatadown 18.4%ViaSatdown 9.5%Chemoursdown 9.4%Match Groupdown 9.1%Pinterestdown 9.1%AMDdown 8.7%Lucid Groupdown 7.8%DaVitadown 7.3%SpaceXdown 7.2%Lattice Semiconductordown 6.5%Coupangdown 6.1%
Travere Therapeutics Chief Research Officer Plans to Retire in February 2027
Travere Therapeutics "announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research and development and CMO."
Travere Therapeutics FILSPARI Shows Positive Long-Term Results in FSGS Treatment
Travere Therapeutics announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension of FILSPARI in the treatment of focal segmental glomerulosclerosis. Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI at the start of the OLE subsequently demonstrated rapid and sustained reductions in proteinuria similar to those who initiated FILSPARI at the beginning of the double-blind period. The results were presented at the European Renal Association 2026 Congress in Glasgow, Scotland June 3-6. The Phase 3 DUPLEX Study is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial that assessed the efficacy and safety of FILSPARI in patients with biopsy-proven or genetic FSGS compared to maximum labeled dose irbesartan for up to 108 weeks. At the end of the double-blind period, all patients were eligible to enroll in the open-label extension portion of the trial following a 4-week washout period and receive FILSPARI for up to three additional years. During the DUPLEX double-blind period, patients treated with FILSPARI achieved higher rates of complete and partial remission compared to maximum labeled dose irbesartan. Complete remission (urine protein-to-creatinine ratio, UPCR less than0.3 g/g) was achieved by 18.5% of FILSPARI-treated patients compared to 7.5% of those who received irbesartan, while partial remission (UPCR less than1.5 g/g) was achieved by 69.0% and 50.8% of patients, respectively. Following transition to the OLE, patients who remained on FILSPARI maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Among these patients, 37.5% achieved complete remission at any time across the double-blind or OLE period, and 87.5% achieved partial remission. Patients who transitioned from irbesartan to FILSPARI in the OLE after washout experienced rapid and sustained reductions in proteinuria, consistent with the reductions observed among patients who began FILSPARI during the double-blind period. Among these patients, 28.9% achieved complete remission at any time across the double-blind or OLE period, and 74.6% achieved partial remission. FILSPARI was generally well tolerated during the long-term OLE follow-up in the study with a safety profile consistent with previous findings.
Travere Enters Exclusive Licensing Agreement with Everest
Travere Therapeutics entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib, a covalent reversible Bruton's tyrosine kinase inhibitor in all markets outside China and certain countries in East and Southeast Asia. Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney diseases, including primary membranous nephropathy, with planned evaluation in focal segmental glomerulosclerosis, minimal change disease and potentially additional indications. BTK is a key mediator of B-cell receptor signaling and plays an important role in B-cell activation, maturation, proliferation, and differentiation into antibody-producing cells. In immune-mediated kidney diseases, B-cell activation and autoantibody production are believed to contribute directly to kidney injury. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. Civorebrutinib has been generally well tolerated throughout the development program to date. As innovation in rare kidney diseases continues to accelerate, patients still face significant unmet need and limited treatment options across many serious conditions. Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. Civorebrutinib may also broaden future treatment approaches in FSGS, where both nephroprotective and targeted immune control approaches may play important roles. Under the terms of the agreement, Everest will receive an upfront payment of $112.5M in exchange for granting Travere exclusive development and commercialization rights for civorebrutinib in all markets outside of China and certain countries in East and Southeast Asia. Everest is also eligible to receive up to approximately $1.03B in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Travere Therapeutics Receives Patent Allowance for Kidney Disease Treatment
Travere Therapeutics last night announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using Filspari in IgA nephropathy. "Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in IgA nephropathy into October 2037. The allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere expects to submit the issued patent for listing in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations - commonly known as the "Orange Book" - promptly following grant," the company stated.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.